Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension
JACC. Case reports, 2026;:110452
Glucagon-like Peptide-1-based and Emerging Cardiometabolic Therapies in Heart Failure with Preserved Ejection Fraction: Linking Molecular Mechanisms to Clinical Outcomes
Cardiac failure review, 2026;12:e33
Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases
Frontiers in oral health, 2026;7:1907109
GLP-1-Based therapies for obesity-related heart failure with preserved ejection fraction: an umbrella review incorporating broader heart failure and cardiometabolic evidence
Frontiers in cardiovascular medicine, 2026;13:1930278
GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review
International journal of molecular sciences, 2026;27(19)
Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Cureus, 2026;18(9):e117270
Lithium Toxicity Following Initiation of Semaglutide in a Patient With Bipolar Disorder: A Case Report
Cureus, 2026;18(9):e117235
GLP-1R agonist semaglutide protects human forebrain organoids from cholesterol-induced neurotoxicity
Alzheimer's & dementia : the journal of the Alzheimer's Association;22(10):e71888
Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes
Journal of managed care & specialty pharmacy;32(10):1173-1188
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition;41(5):1318-1333
Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes
European heart journal, 2026
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
The New England journal of medicine, 2026
Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis
Diabetes, obesity & metabolism, 2026
Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2026
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Lancet (London, England), 2026
[Non-arteritic anterior ischemic optic neuropathy associated with tirzepatide (Mounjaro®): A case report documented by multimodal imaging]
Journal francais d'ophtalmologie, 2026;49(9):104990
Tirzepatide among patients with psoriasis and obesity
Medicina clinica, 2026;166(12):107618
Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study
Endocrine journal, 2026
Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review
Women's health nursing (Seoul, Korea), 2026;32(3):180-189
Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis
Frontiers in pharmacology, 2026;17:1936967